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Summary.-Chronic administration of 17p-oestradiol (via drinking water) or the
oral contraceptive Enovid (norethynodrel and mestranol) (0-1 mg injected s.c. twice
weekly) to nulliparous C3H/HeJ female mice, beginning at one month of age and
terminating at 20 months (17p-oestradiol) or 22 months (Enovid), significantly
increased the incidence of mammary tumours over solvent-treated controls. Con-
current treatment ofthe steroid-treated mice with2-bromo-a-ergoq'yptine (CB-154)
(0.1 mg s.c. injected daily) significantly reduced mammary tumour incidence and
mammary hyperplastic nodule development to the control level. CB-154 is an
efficacious inhibitor of pituitary prolactin secretion. These results demonstrate
that steroid-induced mammary gland dysplasias can be sharply reduced by chronic
CB-154 treatment, and suggest that some of the mammary tumorigenic activities
of oestrogenic steroids in C3H mice are mediated via an increased secretion of
pituitary prolactin.
IT HAS BEEN REPORTED by a number of
laboratories (Cutts and Noble, 1964; Gass,
Brown and Okey, 1974) since the pioneer-
ing studies of Lacassagne (1933), that
chronic administration ofoestrogenic ster-
oids to certain strains of mice consistently
increases the incidence of mammary
tumours. Chronic treatment ofmice with
a number ofoestrogenic steroid-containing
oral contraceptives, on the other hand, has
yielded conflicting results. Rudali, Coezy
and Chemama (1972) and Heston, Vlaha-
kis and Desmukes (1973) were unable to
observe any increase in mammary tumour
incidence in mice treated with oral con-
traceptives, whereas Kahn and Baker
(1969) demonstrated that these steroid
preparations did cause mammarytumours.
Oestrogens, as well as steroid-contain-
ing oral contraceptives, increase prolactin
secretion in rodents (Meites and Nicoll,
1966; Minaguchi andMeites, 1967; Welsch
and Meites, 1969) and such an increase has
been frequently correlated with an in-
creased incidence of mammary tumours
(Miihlbock and Boot, 1959; Kwa, van der
Gugten and Verhofstad, 1969; Welsch,
Nagasawa and Meites, 1970). This has
led to the well known hypothesis, origi-
nally proposed by Furth and colleagues
(Furth, 1968), that oestrogens are mam-
mary oncogenic primarily because of
their stimulatory effect on prolactin
secretion.
The recent availability of a number of
potent prolactin-inhibiting drugs has pro-
vided us with an opportunity to evaluate
prolactin more thoroughly in a number of
physiological and pathological processes.
2-Bromo-ac-ergocryptine (CB-154), one of
the most effective prolactin suppressors in
the ergot alkaloid series (Fluckiger, 1972),
sharply reduces prolactin secretion in
normal as well as in oestrogen-treated
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rodents (Brooks and Welsch, 1974; Gala
and Boss, 1975). Indeed, increased secre-
tory rates ofprolactin, which occur during
lactation or drug-mediated hypothalamic
tranquillization or following placement of
hypothalamic lesions, can also be sharply
suppressed by treatment with a number of
ergot alkaloids (Welsch and Morford,
1974; Arai, Suzuki and Masuda, 1972;
Welsch et al., 1971). It appears that
CB-154 is specific for prolactin, at least in
rodents; i.e., the drug does not appear to
interfere directly with other hormonal
processes. Mice chronically treated with
the ergot have normal oestrous cycles,
suggesting that the ergot has no marked
inhibitory effect on gonadotrophin secre-
tion (Yanai and Nagasawa, 1970; Welsch
and Gribler, 1973). Furthermore, growth
hormone content ofpituitaries (Yanai and
Nagasawa, 1970) and blood (Sinha, Selby
and Vanderlaan, 1974) of mice treated
with CB-154 differs insignificantly from
that of controls.
Recently, we reported that chronic
CB-154 suppression of prolactin secretion
in young nulliparous C3H/HeJ mice
virtually prevented the appearance of
spontaneous mammary tumours (Welsch
and Gribler, 1973). The prolactin-sup-
pressed mice had, in addition, very few
mammary hyperplastic nodules and a
hypoplastic mammary epithelium. Fur-
thermore, the oestrous cycles were normal
in these mice, suggesting that mammary
tumorigenesis can be blocked, even in
mice with normal ovarian activity, as long
as prolactin secretion is kept minimal. It
is unknown, and therefore the focus ofthis
study to determine, whether or not
chronic CB-154 treatment can similarly
block spontaneous mammary tumori-
genesis in young C3H mice concurrently
treated with oestrogenic steroids.
MATERIALS AND METHODS
All animals used in this study were C3H/
HeJ female mice, MTV-positive, obtained
from the Jackson Laboratories, Bar Harbor,
Maine. They were housed in a temperature-
(24 ± 1°C) and light-controlled (14 h/day)
room and provided a diet ofWayne Lab Blox
(Allied Mills, Inc., Chicago, Ill.) and water ad
libiturn.
Four hundred and ninety-nine 30-day-old
female mice were randomly divided into 5
groups. Two groups of mice received 17fl-
oestradiol via drinking water; one of these
groups concurrently received daily injections
of 0.1 mg CB-154. Two additional groups
receivedtwice-weekly(MondayandThursday)
injections of01 mg ofEnovid (norethynodrel,
98.5% and mestranol, 1.5%); one of these
groups concurrently received daily injections
of0-1 mg CB-154. A fifth group was treated
daily with the diluent only and served as
controls. 17,3-Oestradiol was initially dis-
solved in a minimal amount of ethanol and
added to the drinking water at a concentra-
tion of0 5 mg/l. We have previously report-
ed that this dose level induces constant
vaginal cornification in ovariectomized C3H
mice (Brooks and Welsch, 1974). The pre-
paration ofthe Enovid given to the mice was
made by mixing powdered Enovid with
powdered gum arabic and a minimal amount
ofethanol, and diluting to volume with 0-9%
NaCl solution. The CB-154 solution was
prepared by dissolving the drug in a minimal
amount of ethanol and diluting to volume
with 0-9% NaCl solution. All injections
were 0.1 ml and given s.c.
All treatments were maintained until the
death of the animal or termination of the
study. All mice were examined weekly for
palpable mammary tumours. The 17/3-
oestradiol-treated mice were killed after 19
months of treatment (20 months of age); the
Enovid-treated mice and controls were killed
after 21 months of treatment (22 months of
age). Inguinal mammary glands of these
animals were excised and prepared for whole-
mount evaluation. Mammary glands were
rated for development according to the fol-
lowing criteria: few ducts, few or no end
buds = 1I0; moderate duct growth, moderate
number of end buds = 2-0; numerous ducts
and branches, many end buds = 3-0; numer-
ous ducts and branches, minimum lobulo-
alveolar growth = 4 0; numerous ducts and
branches, moderate lobulo-alveolar growth =
5-0 and numerous ducts and branches, dense
lobulo-alveolar growth as inlate pregnancy =
6-0. The number of hyperplastic nodules
was couDted in the wholemount preparations.
Only hyperplastic nodules equal to or greater
than 0 5 mm in diameter were recorded.
323C. W. WELSCH ET AL.
Wholemount preparations were examined
under ten-fold magnification and coded prior
to grading. Mammary tumours were excised,
fixed in Bouin's fluid and evaluated histo-
logically for tumour confirmation.
Mean differences between numbers of
hyperplastic nodules and between latency
periods (days) of mammary tumour appear-
ance were evaluated statistically by Student's
t test. Mean differences between mammary
gland development were evaluated statisti-
cally by the nonparametric Wilcoxon rank
procedure test. Differences in mammary
tumour incidence were evaluated statistically
by chi-square analysis.
RESULTS
Chronic administration of either 17,8-
oestradiol or Enovid to C3H/HeJ female
mice significantly (P < 0 001) increased
the incidence of mammary tumours in
these animals (Figs 1 and 2). Mammary
tumour incidence was 11-14% in the
control group in contrast to 27-30% in the
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FIG. 1. Effects of 17fl-oestradiol and 17f-oestradiol/CB-154 treatments on the incidence of mammary
tumours (MT) in C3H/HeJ female mice. 17/?-Oestradiol was added to the drinking water. 17fl-
Oestradiol vs 17/-oestradiol/CB-154 or controls, P < 0-001. Mean latent period of mammary
tumour appearance (days) s.e. are: controls, 534 ± 24; 17jl-oestradiol, 519 + 11 and 17,-
oestradiol/CB-154, 537 ± 8.
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CONTROLS
11/100 with MT -* 0 * 0 * S
11% MT incidence * 0
* 0
OESTRADIOL
0-5mg/l of drinking H2O
27/99 with MT- * * * o * 0 0 0
27% MT incidence * * 0 0 0 *
OESTRADIOL +CB-154
0-5mg/l of drinking H20 daily CB-154
(0-1 mg/mouse) injections
9/100 with MT >**0
9% MT incidence**o
*t
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CONTROLS
14/100 with MT -. 0
14% MT incidence
ENOVID
0-1 mg/mouse twice weekly injections
30/100 with MT-- * * *
30% MT incidence * .
ENOVID+CB-154
0-1 mg/mouse twice weekly injections
daily CB-154 (0-1 mg/mouse) injections
10/100 with MT-*
10% MT incidence
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FIG. 2.- Effects of Enovid and Enovid//CB-154 treatments on the incidence of mammary tumours in
C3H/HeJ female mice. Enovid was injected s.c. twice weekly. Enovid vs Enovid/CB-154 or
controls, P < 0 001. Mean latent period of mammary tumour appearance (days) ± s.e. are:
controls, 558 ± 24; Enovid, 543 ± 84 and Enovid/CB-154, 588 i 21.
17,-oestradiol- and Enovid-treated groups,
respectively. Chronic administration of
CB-154 to the 17,8-oestradiol- and Enovid-
treated micereduced mammarytumours to
90 (P < 0.001) and 10% (P < 0.001)
respectively, a tumour incidence statisti-
cally indistinguishable from that of the
controls. Mean latency period of tumour
development appeared to be longer in the
CB-154/steroid-treated mice than in the
mice treated with the steroids alone,
although this difference did not reach the
500 level of significance (Figs 1 and 2).
Chronic CB-154 treatment also signifi-
cantly (P < 0.05) reduced the number of
hyperplastic nodules in the inguinal ma,m-
mary glands and significantly (P < 0.05)
reduced normal mammary development
(Table).
Chronic treatment of mice with 17/?-
oestradiol or Enovid appeared to reduce
body weight gains slightly but, because of
animal variability, this reduction was not
significant at the 5% level of significance.
Chronic CB-154 treatment did not have
any effect on body weight gains. Rates of
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TABLE.-Effects ofChronic Treatment of Young Nulliparous C3H/HeJ Mice with CB-154,
17/3-Oestradiol and/or Enovid on Number of Mammary Hyperplastic Nodules and










































100 33 23-9±0-6 4-3±0-6 * 3-1 (1-5-5-0)V*
100 30 22-6±0-5 2 8±0 5} 2-4(1-5-4-0)f
a Treatments began at one month ofage. 17fl-Oestradiol was added to the drinking water. Enovid was
injected s.c. twice weekly. CB-154 was administered daily. Controls and Enovid-treated mice were killed
at 22 months of age. 17fl-Oestradiol treated mice were killed at 20 months of age.
b Arbitrary scale (see text).
c Mean ± s.e.
* P for difference < 0 05.
oestradiol-treated and CB-154/Enovid-
treated mice were statistically indistin-
guishable, therefore the numbers ofmice at
risk in each group throughout this study
were similar. Rate ofdeath (non-tumour
related) in the Enovid-treated mice was
less than in the other groups, thus raising
slightly the number of animals at risk in
this group. To compensate for the in-
creased number of mice at risk in the
Enovid-treated group, ariskfactorstatisti-
cal analysis was performed which demon-
strated that there was an actual significant
increase in the incidence of mammary
tumours in that group.
DISCUSSION
Chronic administration of 17,/-oestra-
diol to the mice in this study sharply
increased the incidence of mammary
tumours, results which are consistent with
a number of earlier reports (Lacassagne,
1933; Gass et al., 1974). The increased
incidence of mammary tumours in the
Enovid-treated mice, very similar to that
in the 17,8-oestradiol-treated mice, is in
accord with the observations of Kahn and
Baker (1969)who demonstrated thattwice-
weekly s.c. injections of norethynodrel
(125 ,ug/20 g body wt), the major steroidal
component of Enovid, induced marked
hyperplastic and neoplastic mammary
development in nulliparous female C3H/
HeJ mice. Rudali et al. (1972) and
Heston et al. (1973), however, failed to
observe any mammary tumorigenic effect
of Enovid (norethynodrel, 98.5% and
mestranol, 1.5%). They added the ste-
roidal preparations to the diet (5-20 ,ug/g
food) and used a different strain of C3H
mice, anexperimentalvariationwhichmay
explain these differing results.
Concurrent administration of CB-154
tothe steroid-treated micesharplycounter-
acted this increased mammary tumour
development, as the cumulative incidence
of tumours in these animals was one-third
that observed in the mice treated with the
steroids alone. Although this is a sub-
stantial reduction in tumour incidence, it
is clear that mammary tumorigenesis was
not totally blocked in this experimental
approach as it had been previously when
CB-154 alone was chronically administered
to C3H/HeJ female mice (Welsch and
Gribler, 1973).
It is well established that CB-154 is an
effective suppressor of prolactin secretion.
This has been consistently demonstrated
in all species tested: e.g., mice (Yanai and
Nagasawa, 1970; Sinha et al., 1974), rats
(Brooks and Welsch, 1974; Gala and Boss,
1975), domestic animals (Karg, Schams
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and Reinhardt, 1972), and man (Lutter-
beck et al., 1971; Rozeneweig et al., 1973).
The ergot can also suppress prolactin
secretion in rodents treated with oestrogen
(Brooks and Welsch, 1974; Gala and Boss,
1975), which is well known to enhance
prolactin secretion (Meites and Nicoll,
1966). Although radioimmunoassay
values for blood prolactin in CB-154/
oestrogen-treated rats are much lower
than in rats treated with the steroid alone,
these values still appear to be higher than
those observed in untreated control rats
(Gala and Boss, 1975). This apparent
inability of CB-154 to suppress prolactin
secretion totally in steroid-treated rodents
may explain, at least in part, why the
ergot did not completely block steroid-
induced mammary tumorigenesis. We
cannot state with absolute certainty that
this is the case, as we did not measure the
blood levels of prolactin in these animals.
Unfortunately, a radioimmunoassay for
mouse prolactin is not yet readily avail-
able.
The sharp reduction in steroid-induced
mammary tumour incidence by simul-
taneous treatment with CB-154 was also
accompanied by a parallel reduction in
the number of mammary hyperplastic
nodules, lesions which in the mouse are
reportedly preneoplastic (DeOme et al.,
1959). Suppression of steroid-induced
hyperplastic and neoplastic mammary
dysplasias by CB-154, as reported in this
study, maybeclinicallyrelevant. Women
receiving oestrogen replacement therapy,
or those consuming oral contraceptives,
mayexperience dysplastic epithelial breast
changes (Hertz, 1968; Haagensen, 1971;
Fasal and Paffenbarger, 1975; Hoover
et al., 1976). It was reported recently
that the chronic use ofoestrogens (Hoover
et al., 1976) or steroid-containing oral
contraceptives (Fasal and Paffenbarger,
1975), particularly by women with a
historyofbenign disease ofthe breast, may
lead to an increased incidence of breast
carcinoma. It would be of great interest
to determine whether or not concurrent
treatment ofthese women with drugs such
as CB-154 would suppress or prevent these
dysplastic epithelial breast changes. CB-
154 has already been used extensively and
successfully as a prolactin suppressor in
womentohaltpuerperalandnon-puerperal
lactation (del Brun et al., 1973; Lutterbeck
et al., 1971).
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